(Q53589005)

15 May 2018

title

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. (English)

1 reference

15 May 2018

1 reference

Sagaster V

1

1 reference

15 May 2018

Ludwig H

2

1 reference

15 May 2018

Kaufmann H

3

1 reference

15 May 2018

Odelga V

4

1 reference

15 May 2018

Zojer N

5

1 reference

15 May 2018

Ackermann J

6

1 reference

15 May 2018

Küenburg E

7

1 reference

15 May 2018

Wieser R

8

1 reference

15 May 2018

Zielinski C

9

1 reference

15 May 2018

Drach J

10

1 reference

15 May 2018

publication date

9 November 2006

1 reference

15 May 2018

published in

Leukemia

1 reference

15 May 2018

volume

21

1 reference

15 May 2018

issue

1

1 reference

15 May 2018

page(s)

164-168

1 reference

15 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404459

exact match

0 references

cites work

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

Genetics and cytogenetics of multiple myeloma: a workshop report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

Gene expression profiling and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

7 January 2021

Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

7 January 2021

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

7 January 2021

Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

7 January 2021

Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

7 January 2021

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

7 January 2021

Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404459

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404459

1 reference

15 May 2018

1 reference

15 May 2018